

Ausgewählte Publikationen von Dr. B.-A. Kallmann

B.A.Kallmann, V.Hummel, T.Lindenlaub, K.Ruprecht, K.V.Toyka, P.Rieckmann

Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1

Brain 2000; 123: 687-697

V.Hummel, **B.A.Kallmann**, T.Füller, S.Wagner, A.Bayas, J.Tonn, E.Benveniste, K.V.Toyka, P.Rieckmann

The production of MMPs in human cerebral endothelial cells and their role in shedding of adhesion molecules

Journal of Neuropathology and Experimental Neurology 2001; 60: 320-327

B.A.Kallmann, P.Rieckmann

Chemokines and MS lesion development

International Journal of Multiple Sclerosis 2002; 9: 100-107

G.Martino, L.Adorini, P.Rieckmann, J.Hillert, **B.A.Kallmann**, G.Comi, M.Filippi

Inflammation in multiple sclerosis: the good, the bad, and the complex

Lancet Neurology 2002; 1: 499-509

B.A.Kallmann, S.Wagner, V.Hummel, A.Bayas, J.C.Tonn, P.Rieckmann

Characteristic gene expression profile of primary human cerebral endothelial cells

FASEB J Express, February 12, 2002, 10.1096/fj.01-0594fje

P.Flachenecker, T.Kümpfel, **B.A.Kallmann**, M.Gottschalk, O.Grauer, P.Rieckmann, C.Trenkwalder, K.V.Toyka

Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters

Multiple Sclerosis 2002; 8: 523-526

U. Michel, **B.A. Kallmann** , P. Rieckmann , D. Isbrandt

UM 9(5)h and UM 9(5)p, a human and a porcine non-coding transcript with preferential expression in the cerebellum

RNA 2002; 8: 1538-1547

-
B.A.Kallmann, J.Sauer, M.Schließer, M.Warmuth-Metz, P.Flachenecker, G.Becker, P.Rieckmann, M.Mäurer

Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS) – A two year follow-up study

J Neurol 2004; 251: 30-34

P.Rieckmann, **B.A.Kallmann**

Neue Therapieansätze bei Multipler Sklerose

Nervenheilkunde 2005; 4: 294-300

B.A. Kallmann, S. Büttner, K.V. Toyka, K.Reiners, P. Rieckmann

Predictive value of evoked potentials for long term disease course in Multiple Sclerosis.

Multiple Sclerosis 2006; 12: 58-65

P. Rieckmann, **B.A. Kallmann**, M. Mäurer, A. Kroner

The Val66Met BDNF Polymorphism in Multiple Sclerosis: Potential Biomarker for Treatment Response to Glatiramer Acetate

Neurology 2008; Suppl.1: P07.126

P.Rieckmann , **B.A.Kallmann**, V.Hummel, A.Müller, S.Wiese

Exploring the neuro-vascular niche as potential target for treatment in MS

Multiple Sclerosis 2008; 14 Suppl.1: P202

P.Rieckmann, N.Kruse, **B.A.Kallmann**, V.Leussink, M.Mäurer, F.Bergh, T.Weber

Beneficial effects of pregnancy in MS reflected by cytokine pattern and prolactin

Multiple Sclerosis 2008; 14 Suppl.1: P720

-

Multiple-Sklerose-Therapie-Konsensus-Gruppe (MSTKG)

Immunmodulatorische Stufentherapie der Multiplen Sklerose. 1. Ergänzung:
Dezember 2000

Nervenarzt 2001; 72: 150-157

Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und
praktische Umsetzung, März 2002

Nervenarzt 2002; 73: 556-563

Escalating immunotherapy of multiple sclerosis. New aspects and practical
application

Journal of Neurology 2004; 251: 1329-1339

Immunmodulatorische Stufentherapie der Multiple Sklerose – aktuelle
Therapieempfehlungen (September 2006)

Nervenarzt 2006; 77: 1506-1518

Basic and escalating immunomodulatory treatments in multiple sclerosis: Current
therapeutic recommendations

J Neurol. 2008; 255:1449-1463

Arbeitsgruppe Moderne Immuntherapie der MS des Ärztlichen Beirats der Deutschen Multiple Sklerose Gesellschaft

Therapie der Multiplen Sklerose mit monoklonalen Antikörpern

Akt Neurol 2009: DOI 10.1055/s-0029-1220429